Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227 Meeting Abstract
| Authors: | Hellmann, M. D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Otterson, G.; Audigier-Valette, C.; Minenza, E.; Linardou, H.; Burgers, S.; Salman, P.; Borghaei, H.; Ramalingam, S. S.; Brahmer, J.; Reck, M.; O'Byrne, K. J.; Geese, W. J.; Green, G.; Chang, H.; Szustakowski, J. D.; Bhagavatheeswaran, P.; Healey, D.; Fu, Y.; Nathan, F.; Paz-Ares, L. |
| Abstract Title: | Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227 |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468818900070 |
| DOI: | 10.1158/1538-7445.Am2018-ct077 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT077 -- Source: Wos |
